Log in

NASDAQ:CASI - CASI Pharmaceuticals Stock Price, Forecast & News

$3.16
+0.01 (+0.32 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$3.11
Now: $3.16
$3.18
50-Day Range
$3.14
MA: $3.28
$3.50
52-Week Range
$2.83
Now: $3.16
$4.58
Volume52,164 shs
Average Volume117,298 shs
Market Capitalization$304.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.15 per share

Profitability

Net Income$-27,470,000.00

Miscellaneous

Employees124
Market Cap$304.47 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.


CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals Inc (NASDAQ:CASI) announced its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. The biotechnology company had revenue of $2.79 million for the quarter, compared to the consensus estimate of $0.70 million. View CASI Pharmaceuticals' Earnings History.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for CASI Pharmaceuticals.

What price target have analysts set for CASI?

1 Wall Street analysts have issued twelve-month price objectives for CASI Pharmaceuticals' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate CASI Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 121.5% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals.

What is the consensus analysts' recommendation for CASI Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals.

Has CASI Pharmaceuticals been receiving favorable news coverage?

News headlines about CASI stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CASI Pharmaceuticals earned a news impact score of -1.9 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for CASI Pharmaceuticals.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a decline in short interest during the month of November. As of November 29th, there was short interest totalling 3,180,000 shares, a decline of 13.8% from the November 14th total of 3,690,000 shares. Based on an average daily volume of 138,200 shares, the short-interest ratio is currently 23.0 days. Currently, 8.2% of the shares of the company are short sold. View CASI Pharmaceuticals' Current Options Chain.

Who are some of CASI Pharmaceuticals' key competitors?

What other stocks do shareholders of CASI Pharmaceuticals own?

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the folowing people:
  • Dr. Wei-Wu He, Chairman & CEO (Age 54)
  • Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)
  • Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)
  • Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)
  • Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53)

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wellington Shields Capital Management LLC (1.37%), State Street Corp (0.91%) and Barclays PLC (0.03%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman, China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Institutional Ownership Trends for CASI Pharmaceuticals.

Which institutional investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for CASI Pharmaceuticals.

Which institutional investors are buying CASI Pharmaceuticals stock?

CASI stock was purchased by a variety of institutional investors in the last quarter, including Wellington Shields Capital Management LLC and State Street Corp. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Insider Buying and Selling for CASI Pharmaceuticals.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $3.16.

How big of a company is CASI Pharmaceuticals?

CASI Pharmaceuticals has a market capitalization of $304.47 million. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe.View Additional Information About CASI Pharmaceuticals.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com/.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]


MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel